News | August 06, 2024
OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
Revolutionary technology will further boost OneSource’s scientific services offerings
Revolutionary technology will further boost OneSource’s scientific services offerings
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Strong topline growth driven by solid performance across key brands.
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Subscribe To Our Newsletter & Stay Updated
